I-Mab Overview
Valuation check: IMAB's ROE is -19.42%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow-19.42%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
I-Mab posts a ROE of -19.42%. That is below the Healthcare sector average of 11.15%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 11.15% is typical. I-Mab's -19.42% is lower that level. That is roughly 274.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
I-Mab's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -19.42%; use YoY and peer views to separate noise from signal.
Context for IMAB's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 11.15%), and (3) consistency with growth and profitability. This page covers the first two; I-Mab's other metric pages and overview cover the third.
Judging I-Mab against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -19.42% here, then scan peer and history charts to see if the gap is persistent.
